Petros Grivas

No bio available.

Financial relationships

  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Merck
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    BMS
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    AstraZeneca
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    EMD Serano
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Seattle Genetics
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Pfizer
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Janssen
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Roche
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Astellas Pharma
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Gilead Sciences
    Date added:
    06/15/2024
    Date updated:
    06/15/2024

Pages

Return to Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery